| Autor: |
Watanabe M; The Department of Renal and Urologic Surgery, Asahikawa Medical University., Wada N; The Department of Renal and Urologic Surgery, Asahikawa Medical University., Kita M; The Department of Renal and Urologic Surgery, Asahikawa Medical University., Hori J; The Department of Renal and Urologic Surgery, Asahikawa Medical University., Tamaki G; The Department of Renal and Urologic Surgery, Asahikawa Medical University., Kakizaki H; The Department of Renal and Urologic Surgery, Asahikawa Medical University. |
| Jazyk: |
japonština |
| Zdroj: |
Hinyokika kiyo. Acta urologica Japonica [Hinyokika Kiyo] 2020 Sep; Vol. 66 (9), pp. 289-292. |
| DOI: |
10.14989/ActaUrolJap_66_9_289 |
| Abstrakt: |
We retrospectively investigated the clinical course of α1 blocker discontinuation in patients who had lower urinary tract symptoms with benign prostate hypertrophy (LUTS/BPH) and received combination therapy ofdutasteride and α1 blocker. Among the patients with LUTS/BPH who had been receiving combination therapy, those who wished to reduce the number ofprescribed drugs and discontinue the use of α1 blocker because ofsymptom improvement were recruited in this study. Symptom scores including International Prostate Symptom Score (IPSS) and overactive bladder symptom score (OABSS), parameters ofuroflowmetry and prostate volume (PV) were evaluated at the time of α 1 blocker discontinuation. Twenty-two patients discontinued the use of α 1 blocker. The mean PV at the time of α 1 blocker discontinuation was 43.2 ml, and the mean duration ofcombination therapy was 39.4 months. In 11 (50%) patients, dutasteride monotherapy without α1 blocker was maintained for a mean follow-up of 10.5 months (9-12 months) after α1 blocker discontinuation (Non-resumption group). In the other 11 patients (50%), α1 blocker was resumed because ofthe patient's request to resume the use of α1 blocker (Resumption group). The mean length ofdutasteride monotherapy was 4. 5 months (1-8 months) in the resumption group. Compared with the non-resumption group, IPSS total score and storage sub-score ofIPSS at the time of α1 blocker discontinuation were significantly higher in the resumption group. Based on the ROC curve, IPSS total score <16, IPSS voiding/storage symptom score <7, OABSS <7 and PV 54 ml or more at the time of α1 blocker discontinuation were predictors ofnon-resumption of α1 blocker. These results suggest that if LUTS is controlled by a long-term combination therapy ofdutasteride and α1 blocker and still PV is large enough, α1 blocker can be discontinued. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
